A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours

Bibliographic Details
Main Authors:	Adenis, A, Ray-Coquard, I, Italiano, A, Chauzit, E, Bui-Nguyen, B, Blay, J-Y, Tresch-Bruneel, E, Fournier, C, Clisant, S, Amela, E Y, Cassier, P A, Molimard, M, Penel, N
Format:	Online
Language:	English
Published:	Nature Publishing Group 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833229/

Similar Items

Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial
by: Diane Pannier, et al.
Published: (2018-07-01)

Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate
by: Rajappa, Senthil, et al.
Published: (2013)

What does a modified-Fibonacci dose-escalation actually correspond to?
by: Penel, Nicolas, et al.
Published: (2012)

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)†
by: Bompas, E., et al.
Published: (2015)

Dose escalation of a curcuminoid formulation
by: Lao, Christopher D, et al.
Published: (2006)

A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium
by: Lheureux, S, et al.
Published: (2015)

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
by: Cassier, P A, et al.
Published: (2013)

Predictive Value of Clinical Judgment of Tumour Progression in Phase II Trials
by: Kotecki, Nuria, et al.
Published: (2012)

Phase II study of ‘high-dose’ celecoxib and metronomic ‘low-dose’ cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma
by: Abdel-Bary, N, et al.
Published: (2009)

Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy
by: KIBATA, KAYOKO, et al.
Published: (2013)

Metronomic Chemotherapy: Low Dose Less Toxicity Anticancer Strategy
by: Anjan Khadka, et al.
Published: (2016-06-01)

Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
by: Wong, Eric T., et al.
Published: (2016)

Efficacy of Dose-Escalated Radiotherapy for Recurrent Colorectal Cancer
by: Jo, Sunmi, et al.
Published: (2016)

Biological modelling of the radiation dose escalation effect of regional hyperthermia in cervical cancer
by: Crezee, J., et al.
Published: (2016)

Lichenoid Drug Eruption after Low-Dose Imatinib Mesylate Treatment
by: Lee, Jae-Hyung, et al.
Published: (2013)

Feasibility of extreme dose escalation for glioblastoma multiforme using 4π radiotherapy
by: Nguyen, Dan, et al.
Published: (2014)

Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome
by: Adenis, Antoine, et al.
Published: (2013)

COMBINED RADIATION THERAPY FOR PROSTATE CANCER WITH DOSE ESCALATION BRACHYTHERAPY AND ANDROGEN DEPRIVATION
by: Auchynikau V. A., et al.
Published: (2018-09-01)

Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy
by: Skinner, Heath D, et al.
Published: (2013)

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas
by: Nghiemphu, Phioanh Leia, et al.
Published: (2012)

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors
by: Sylvie Négrier, et al.
Published: (2017-08-01)

Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents
by: Le Tourneau, Christophe, et al.
Published: (2012)

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma
by: Assouline, S E, et al.
Published: (2014)

Radiation Dose Escalation in Stage III Non-Small-Cell Lung Cancer
by: Terakedis, Breanne, et al.
Published: (2011)

PK/PD modeling supports the dose-escalation decision in VIKING
by: Lovern, M, et al.
Published: (2010)

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
by: Tjalf Ziemssen, et al.
Published: (2017-08-01)

Definitive radiotherapy dose escalation with chemotherapy for treating non-metastatic oesophageal cancer
by: Chao-Yueh Fan, et al.
Published: (2018-08-01)

Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma
by: Iida, Shinsuke, et al.
Published: (2016)

Dose-Escalated Radiotherapy for the Treatment of Patients With Recurrent Colorectal Cancer
by: Kim, Hyung Jin, et al.
Published: (2016)

Some small sample properties of the EWOC design in dose escalation trials
by: Kinnersley, Nelson
Published: (2015)

Addressing the barriers to implementing model based designs in dose escalation studies
by: Cornelius, Victoria, et al.
Published: (2015)

Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer
by: Cihoric, Nikola, et al.
Published: (2015)

Oral carvedilol in escalating doses in the acute treatment of atrial fibrillation
by: Chitrapu, Ravi Venkatachelam, et al.
Published: (2014)

Phase I Dose-Escalation Study of Nimustine in Tumor-Bearing Dogs
by: TAKAHASHI, Masashi, et al.
Published: (2014)

Safety of a dose-escalated pre-workout supplement in recreationally active females
by: Vogel, Roxanne M, et al.
Published: (2015)

Dose-Escalated Robotic SBRT for Stage I–II Prostate Cancer
by: Meier, Robert
Published: (2015)

Salvage low-dose-rate 125I partial prostate brachytherapy after dose-escalated external beam radiotherapy
by: Chang, Lynn, et al.
Published: (2014)

Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model
by: Ouyang, Mao, et al.
Published: (2016)

Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer
by: Krzakowski, M., et al.
Published: (2013)

Erlotinib ‘dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
by: Mita, A C, et al.
Published: (2011)